Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | THRB | P10828 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31559931 | 0.84 | KDM4E (0.41) | KDM4EGLAKMT2AMEN1TDP1 | |
| SCHEMBL3980785 | 0.84 | KDM4E (0.41) | KDM4EGLAKMT2AMEN1TDP1 | |
| SCHEMBL28792146 | 0.83 | GPR35 (0.38) | KMT2AMEN1CYP3A4TSHRGPR35 | |
| SCHEMBL29684453 | 0.83 | GPR35 (0.38) | KMT2AMEN1CYP3A4TSHRGPR35 | |
| SCHEMBL29743810 | 0.79 | GRM6 (0.42) | KDM4EGLAKMT2AMEN1TDP1 | |
| SCHEMBL543319 | 0.79 | GRM6 (0.42) | KDM4EGLAKMT2AMEN1TDP1 | |
| SCHEMBL6240526 | 0.79 | TDP1 (0.41) | KDM4EGLAKMT2AMEN1TDP1 | |
| SCHEMBL30280942 | 0.79 | TDP1 (0.41) | KDM4EGLAKMT2AMEN1TDP1 | |
| SCHEMBL4422996 | 0.78 | CYP1A2 (0.41) | RXFP1TSHRGPR35 | |
| SCHEMBL6825576 | 0.78 | CA12 (0.41) | KDM4ECYP3A4MAPTPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110642689-B | 3, 6-dibromo-2-methylbenzaldehyde and chemical synthesis method thereof | 南通大学 | 2022-06-24 | — | — | CN | claimed |
| CN-110642689-A | 3, 6-dibromo-2-methylbenzaldehyde and chemical synthesis method thereof | 南通大学 | 2020-01-03 | — | — | CN | claimed |
| CN-110642689-B | 3, 6-dibromo-2-methylbenzaldehyde and chemical synthesis method thereof | 南通大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-110642689-A | 3, 6-dibromo-2-methylbenzaldehyde and chemical synthesis method thereof | 南通大学 | 2020-01-03 | — | — | CN | disclosed |
| EP-2098513-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-1037632-B1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6825355-B2 | FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE | BRISTOL-MYERS SQUIBB CO. | 2004-11-30 | — | — | US | disclosed |
| WO-2004073612-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO. INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20020123484-A1 | Benzothiazole protein trosine kinase inhibitors | DAS JAGABNDHU (US) | 2002-09-05 | — | — | US | disclosed |
| EP-1037632-A4 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-08-21 | — | — | EP | disclosed |
| CN-1290165-A | Benzothiazole Protein tyrosine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2001-04-04 | — | — | CN | disclosed |
| EP-1037632-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999024035-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123484-A1 | Benzothiazole protein trosine kinase inhibitors | TXK, LTK, JAK2 | KDM4E 1679/4885GLA 4301/4885KMT2A 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.